BACKGROUND: Breast cancer risk estimates for atypical lesions are based primarily on case-control studies of patients with open biopsies. The authors report the cumulative breast cancer incidence after a core biopsy diagnosis of atypical hyperplasia (ductal or lobular) or lobular carcinoma in situ. METHODS: A cohort study with central pathology review was conducted on 393 patients who had core biopsy diagnoses of atypical hyperplasia and lobular carcinoma in situ from 1995 through 2010. Follow-up was available for 255 of 264 patients (97%) at a median of 87 months (range, 3-236 months). RESULTS: There were 212 patients (54%) who were not upgraded on excision and had no personal history of breast cancer. Of these, 21 of 212 (9.9%) developed breast cancer, including 15 invasive carcinomas, 4 ductal carcinomas in situ, 1 pleomorphic lobular carcinoma in situ, and 1 unknown type. The prior core biopsy diagnoses were atypical ductal hyperplasia for 11 patients (52%) and atypical lobular hyperplasia/lobular carcinoma in situ in the remaining 10 patients (48%). The number of atypical foci in the core biopsy was not significantly associated with the subsequent development of breast cancer (P 5.42). Of the 15 invasive carcinomas, 11 (73%) were ipsilateral, 11 (73%) were pathologic T1 tumors, 5 (33%) were pathologic N1 tumors, 13 (87%) were estrogen receptor-positive, and 1 (7%) was amplified for human epidermal growth factor receptor 2. CONCLUSIONS: In patients who had an initial diagnosis of atypical hyperplasia or lobular carcinoma in situ on core biopsy, the 7-year cumulative breast cancer incidence was 9.9%. Most tumors were ipsilateral, stage I, estrogen receptor-positive, invasive carcinomas. The current data support close clinical and radiologic follow-up for more than 5 years in this patient population. Cancer 2018;124:459-65. V C 2017 American Cancer Society.
INTRODUCTION
Atypical hyperplasia (AH) of the breast, which is a diagnostic category of proliferative disease with atypia that includes atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH), is associated with an increased risk for the subsequent development of carcinoma. [1] [2] [3] The risk applies to both breasts, and the majority of cancers develop in the ipsilateral breast. [3] [4] [5] [6] In large case-control studies, the cumulative breast cancer incidence after a diagnosis of AH is approximately 25% to 30% at 25 years. 5, 7, 8 In most studies, the 2 histologic types of AH (ADH and ALH) have a relatively similar frequency of occurrence and similar breast cancer risk. 9 The frequency of AH in large case-control studies of open biopsies was approximately 3% to 4%. 1, 3 Data from the Breast Cancer Surveillance Consortium also provide an estimate of the frequency with which AH and lobular carcinoma in situ (LCIS) are diagnosed in breast biopsies. In an analysis of greater than 76,000 breast biopsies of all types, the rate of diagnosis of AH and LCIS was approximately 4%. 10 These diagnoses appear to account for a similar proportion of coreneedle biopsies (CNBs). 11, 12 Some smaller studies have reported AH or LCIS in 1% or 2% of cases 13, 14 and in up to 10% to 15% of vacuum-assisted stereotactic CNBs. [15] [16] [17] Although the best risk estimates are based on studies of open biopsies-largely from the premammographic era-AH and LCIS are most often diagnosed in contemporary practice by image-guided CNB. Clinical management of these lesions is based primarily on the risk of identifying carcinoma (invasive carcinoma [IC] or ductal carcinoma in situ [DCIS] ) in an excision specimen. 18, 19 After surgical excision, patients may be offered chemoprevention with a selective estrogen receptor (ER) modulator (SERM) (tamoxifen or raloxifene) or an aromatase inhibitor (anastrazole or exemestane) to reduce their future risk of developing carcinoma in either breast. 20, 21 Several studies have examined the rate of upgrade to carcinoma after a CNB diagnosis of ADH, ALH, or LCIS. 12, 22, 23 A recent study of ADH diagnosed on CNB suggests that the 10-year risk estimates for patients diagnosed on CNB may be lower than that for those diagnosed by open biopsy. 24 The objective of the current study was to determine the incidence of subsequent breast carcinoma in a group of patients with a CNB diagnosis of AH or LCIS who were not upgraded to breast cancer on an initial diagnostic excisional breast biopsy.
MATERIALS AND METHODS
This study was approved by the Cleveland Clinic Institutional Review Board with a waiver of consent. Pathology reports for 442 cases of AH (ADH, ALH, or both) or LCIS diagnosed on CNB from 1995 through 2010 were retrieved from the Anatomic Pathology information system CoPath Plus (Cerner Corporation, Kansas City, MO). The 49 CNBs that were excluded after initial pathology report and slide review contained usual-type hyperplasia only, nonclassical LCIS (either pleomorphic LCIS or florid LCIS with central necrosis), or an atypical glandular proliferation suspicious for IC. An excision pathology report was available for 349 of the remaining 393 cases (89%). Each core biopsy was individually correlated with a corresponding excision specimen when possible. Upgrades to breast cancer were defined as IC of any histologic type DCIS, or pleomorphic LCIS on excision. Core biopsy slides and excision pathology reports were reviewed by dedicated breast pathologists (B.C.C., C.D.S.). The pathologic features of the cases that were upgraded to carcinoma were documented.
Of the CNB cases that were not upgraded, slides were available for 214 of 264 (81%); and diagnoses of ADH (59%), ALH/LCIS (34%), or ADH and ALH/ LCIS (7%) were confirmed using established histopathologic criteria (Fig. 1A,B) . 4, 8, 25, 26 Slides were available for 105 of 129 upgraded cases (81%) (Supporting Material; see online supporting information). The number of atypical foci and whether a case was reported as cannot exclude or suspicious for DCIS were recorded. The majority of CNBs that were suspicious for DCIS had either a lownuclear-grade intraductal proliferation partially involving ducts and lobular units or cytologic features approaching nuclear grade 2 DCIS that were limited to 1 or 2 duct spaces or an area <2 mm. 27 The patient's age and indication for CNB were recorded. Breast Imaging Reporting and Data System (BI-RADS) scores were available for a total of 371 patients, including 122 of those who were upgraded on excision and 249 who were not upgraded. Calcifications or architectural distortion without an ultrasound correlate were biopsied with a stereotactic technique using the Suros ATEC or Eviva 12-gauge core-biopsy device (both from Hologic, Inc., Marlborough, MA). Six to 12 cores were routinely obtained, and additional passes were performed at the discretion of the radiologist. Ultrasound findings were biopsied with a 14-gauge core-biopsy device (C. R. Bard, Inc, Tempe, AZ). Specimen radiography was routinely performed for core biopsies performed for calcifications. The CNB sites were marked with clips and confirmed with postclip mammography. At our institution, all patients who were diagnosed with ADH, ALH, or LCIS on CNB were referred for surgical consultation. The patients who underwent surgery had needle-localized excisional biopsies with confirmation of the biopsy site in the excision specimens.
Treatment data and patient demographics for the 264 patients (67%) who were not upgraded were obtained from the electronic medical record (Epic Systems Corporation, Verona, WI). Concurrent ipsilateral or contralateral breast cancers were defined as those diagnosed: 1) contemporaneously (ie, in a separate CNB specimen from the same core-biopsy procedure) or 2) in a separate CNB obtained within 90 days of the CNB with ADH, ALH, or LCIS, often as a result further evaluation and imaging (eg, magnetic resonance imaging in patients with dense breast tissue and second-look ultrasounds). The follow-up interval was calculated from the date of CNB to the date of the most recent mammogram or progress note from a breast oncologist or primary care physician. The pathologic features of the subsequent breast cancer (Fig. 1C,D) were extracted from pathology reports in the Anatomic Pathology information system. Chemoprevention data were verified by prescriptions for an SERM or aromatase inhibitor in the electronic medical record. P values were calculated using chi-square tests, Fisher exact tests, and MannWhitney U tests.
RESULTS
The clinical and pathologic features of the patients who had CNB diagnoses of ADH and ALH/LCIS are summarized in Table 1 . Of the 393 cases, 129 (33%) were upgraded to carcinoma on excision. The patients' histories of concurrent breast cancer, indications for CNB, or types of CNB were not significantly associated with being upgraded on an initial excisional biopsy. The patients who were upgraded tended to be slightly older than those who were not upgraded (P 5 .008). The number of patients who had a BI-RADS score of 5 was higher in the group that was upgraded to carcinoma on excision (P 5 .017), but there were relatively few BI-RADS scores of 5 in this series overall (ie, approximately 3%). Additional data and a discussion of the upgraded cases are provided in the Supporting Material (see online supporting information).
The mean age of the 264 patients who were not upgraded to carcinoma was 57 years. Clinical follow-up was available for 255 of 264 patients (97%) who were not upgraded, and the median follow-up was 87 months (range, 3-236 months). The distribution of CNB diagnoses for the 264 patients who were not upgraded was as follows: ADH, 60%; ALH/LCIS, 34%; or a combination of ADH and lobular neoplasia, 6%. When the 52 of 264 patients (20%) with a history of prior or concurrent breast cancer were excluded, the distribution of CNB diagnoses was similar for the remaining 212 patients (ADH, 61%; ALH/LCIS, 33%; or a combination of ADH and lobular neoplasia, 6%; P 5 .98). Of the 212 patients who were not upgraded on excision and who did not have a personal history of breast cancer, 21 (9.9%) subsequently developed breast cancer. In these patients, the median time to breast cancer diagnosis was 71 months (range, 15-155 months). The earliest diagnoses of IC and DCIS were both contralateral to the prior CNB and occurred at 15 and 22 months of follow-up, respectively. The number of breast cancer diagnoses for each 1-year interval in the first 10 years of follow-up is illustrated in Figure 2 . The distribution of subsequent breast cancer is fairly even over the follow-up period without a peak or plateau in incidence.
The 21 breast cancers included 15 ICs, 4 DCIS, 1 pleomorphic LCIS, and 1 of unknown type. Imaging studies with data on the locations of CNBs and subsequent breast cancer were available for 13 of the 14 ipsilateral breast cancers (invasive and noninvasive). Of those 13 breast cancers, 6 (46%) developed in the same quadrant as the original CNB, and 7 (54%) developed in another quadrant. The prior CNB diagnoses of those who developed breast cancer were essentially equally split between ADH (11 of 21 patients) and ALH/LCIS (10 of 21 patients). There was no significant difference in the number of AH foci between patients who did and did not develop carcinoma (P 5 .42). There was no significant difference in the frequency of chemopreventive therapy between those who did (14%) and did not (13%) develop carcinoma (P 5 .88). The clinicopathologic features of the 15 ICs are summarized in Table 2 . There were 12 invasive ductal carcinomas, 2 invasive lobular carcinomas, and 1 IC with mixed ductal and lobular histology. The ICs were predominantly ipsilateral (73%), pathologic T1 (pT1) (73%), ER-positive (87%), human epidermal growth factor receptor 2-negative (93%) tumors. Five patients (33%) had pathologic lymph node involvement (pN1) (Fig. 1) .
DISCUSSION
In this large group of patients who had ADH, ALH, and LCIS of the breast diagnosed on CNB, we analyzed the subsequent breast cancer incidence specifically in those who had no personal history of breast cancer and were not upgraded to carcinoma on an initial diagnostic excisional biopsy. With a median of a little more than 7 years of follow-up, the cumulative breast cancer incidence was Figure 2 . The cumulative incidence of breast cancer over the initial 10 years of follow-up is illustrated for patients who had a core-needle biopsy diagnosis of atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS) that was not upgraded in the initial diagnostic excisional biopsy. approximately 10%. This is slightly higher than the approximately 1% per year breast cancer incidence observed over much longer follow-up periods in the largest case-control studies of patients with AH-a category that encompasses ADH and ALH-in open biopsies.
5,7,8
We did not observe a peak or plateau in breast cancer incidence during the first 10 years of follow-up (Fig. 2) . The majority of ipsilateral breast cancers (invasive and noninvasive) that developed were located in a quadrant different from that of the original CNB. In addition, the earliest cases of subsequent IC and DCIS were both contralateral to the prior CNB and were diagnosed more than 1 year after the initial CNB. In some studies, the breast cancer incidence after a diagnosis of LCIS was similar to that reported for AH. In the Nashville Cohort, the absolute risk for invasive breast cancer after a diagnosis of LCIS in an open biopsy was 17% at 15 years. 8 However, other studies have suggested higher or lower rates of subsequent breast cancer after a diagnosis of LCIS, especially during the first 3 to 6 years of follow-up. In a recently reported study of over 1000 patients with LCIS (presumably diagnosed in open biopsies and CNBs), the cumulative breast cancer incidence was 2% per year for the first 6 years of follow-up and 26% at 15 years. 28 In addition, in studies of ALH and LCIS diagnosed specifically on CNB with clinical-radiologic follow-up only (ie, not immediately excised), the rate of subsequent breast cancer near the core-biopsy site was 2% in the first 3 to 5 years of follow-up. [29] [30] [31] In our series, there were only 20 patients (8%) with LCIS only. Of those 20 patients, 4 developed breast cancer, and their mean time to diagnosis was 5.6 years ( Table 2) .
Most of the subsequent breast cancers in this series were ipsilateral, pT1, low-grade, ER-positive, invasive ductal carcinomas; and one-third had positive lymph nodes (pN1) ( Table 2) . These findings are similar to the data from case-control studies of open biopsies. In the Mayo Clinic Benign Breast Disease Cohort, the overall incidence of breast cancer after a diagnosis of AH was approximately 1% per year with a median time to diagnosis of 8.8 years. 32 Most of the subsequent breast cancers in that cohort also were ipsilateral, low-grade, ER-positive, invasive ductal carcinomas; and 25% had positive lymph nodes. 32 In the Nurses' Health Study, the majority of subsequent ICs were ER-positive, invasive ductal carcinomas. 33 The largest contemporary study of breast cancer risk associated with a diagnosis of ADH on CNB is a series from the imaging registries of the Breast Cancer Surveillance Consortium (BCSS). 24 That study, which did not evaluate DCIS as an endpoint, included 1058 cases of ADH diagnosed on CNB with an estimated 5% risk of IC in the first 10 years of follow-up. 24 It is noteworthy that the risk was slightly higher for patients who were diagnosed with ADH on excisional biopsy (6.7%). In our series, ADH accounted for the majority of CNB cases, and the cumulative IC was similar but slightly higher (7.1%). The BCSS study did not include central pathology review, 24 and variability in the diagnoses of ADH 34 may explain the slight differences in breast cancer incidence. Another explanation could be differences in the uptake of risk-reducing chemoprevention in the patient populations studied. However, receipt of tamoxifen was documented in 7.3% of the patients with ADH in the BCSS study; whereas, in our series, the frequency of chemoprevention was 14% in those who subsequently developed breast cancer and 10% in those who did not. There are conflicting data from the largest casecontrol studies (based primarily on open biopsies) on the correlation between the extent and type of atypia and the future risk of breast cancer. In a combined analysis of the Mayo Clinic and Nashville cohorts, the breast cancer risk associated with AH was significantly higher in patients who had 3 or more foci of atypia. 35 In addition, the risk associated with ADH appeared to be higher than that associated with ALH. 35 However, a similar analysis of the Nurses' Health Study identified no significant correlation between the type and extent of AH and the risk of breast cancer. 36 Possible explanations for these discrepancies could include differences in sample size or, more likely, variations in the application of the criteria for a diagnosis of AH. 37 In our series, CNB diagnoses for patients who developed breast cancer were almost evenly divided between ADH and ALH/LCIS, and we observed no significant difference in the number of AH foci between those who did and did not develop breast cancer (P 5 .42).
Conclusion
In a group of patients with no personal history of breast cancer who had a CNB diagnosis of AH or LCIS that was not upgraded to carcinoma on initial excisional biopsy, 9.9% developed breast cancer, and the median time to diagnosis was approximately 6 years. Most of the subsequent breast cancers were ipsilateral but were not in the same quadrant as the original CNB. The majority of the ICs were pT1, ER-positive, invasive tumors; and 33% involved positive lymph nodes. There was no detectable peak or plateau in breast cancer incidence during the first 10 years of follow-up. The current data support the use of close clinical and radiologic follow-up for more than 5 years in this patient population.
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